Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
SYBX Synlogic, Inc. daily Stock Chart
SYBX [NASD]
Synlogic, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.73 Insider Own0.40% Shs Outstand35.03M Perf Week1.09%
Market Cap64.81M Forward P/E- EPS next Y-1.71 Insider Trans5.66% Shs Float25.29M Perf Month-10.63%
Income-51.40M PEG- EPS next Q-0.43 Inst Own51.70% Short Float6.22% Perf Quarter-28.02%
Sales2.20M P/S29.46 EPS this Y16.40% Inst Trans-14.68% Short Ratio3.39 Perf Half Y-15.91%
Book/sh4.58 P/B0.40 EPS next Y1.70% ROA-27.40% Target Price7.81 Perf Year-76.22%
Cash/sh3.41 P/C0.54 EPS next 5Y- ROE-33.20% 52W Range1.35 - 10.01 Perf YTD-28.29%
Dividend- P/FCF- EPS past 5Y23.60% ROI-34.60% 52W High-81.52% Beta2.08
Dividend %- Quick Ratio15.00 Sales past 5Y- Gross Margin- 52W Low37.04% ATR0.31
Employees76 Current Ratio15.00 Sales Q/Q1009.00% Oper. Margin- RSI (14)44.86 Volatility8.89% 18.49%
OptionableYes Debt/Eq0.00 EPS Q/Q20.90% Profit Margin- Rel Volume0.23 Prev Close2.01
ShortableYes LT Debt/Eq0.00 EarningsMar 12 AMC Payout- Avg Volume464.43K Price1.85
Recom2.00 SMA20-4.44% SMA50-21.19% SMA200-47.76% Volume108,636 Change-7.96%
Aug-21-19Downgrade Oppenheimer Outperform → Perform
Apr-30-19Initiated Jefferies Buy $18
Dec-13-18Initiated Chardan Capital Markets Buy $20
Mar-19-18Initiated H.C. Wainwright Buy $20
Jan-29-18Initiated Piper Jaffray Overweight $16
Mar-30-20 06:00AM  Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities PR Newswire
Mar-15-20 11:00AM  Synlogic, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St.
Mar-13-20 11:16AM  Edited Transcript of SYBX earnings conference call or presentation 12-Mar-20 9:00pm GMT Thomson Reuters StreetEvents +14.39%
Mar-12-20 04:19PM  Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update PR Newswire -9.74%
03:00PM  Synlogic, Inc. to Host Earnings Call ACCESSWIRE
Mar-11-20 04:02PM  Synlogic to Present at Chardan's Virtual Microbiome Medicines Summit PR Newswire -9.41%
Mar-05-20 04:02PM  Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast PR Newswire
Feb-19-20 02:04PM  Some Synlogic (NASDAQ:SYBX) Shareholders Have Taken A Painful 73% Share Price Drop Simply Wall St.
Feb-18-20 04:02PM  Synlogic Announces Participation in Upcoming Investor Conferences PR Newswire +5.83%
Jan-24-20 08:01AM  Will Synlogic Continue to Surge Higher? Zacks
Jan-14-20 08:33AM  BioMarin to Begin Early-Stage Study on Gene Therapy for PKU Zacks +6.23%
Jan-09-20 06:00AM  Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs Business Wire +5.54%
Jan-06-20 09:20AM  Can The Uptrend Continue for Synlogic? Zacks
Dec-20-19 03:29PM  Here is What Hedge Funds Think About Synlogic, Inc. (SYBX) Insider Monkey
Dec-12-19 07:55AM  Will Synlogic Continue to Surge Higher? Zacks
Dec-11-19 06:00AM  Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development Business Wire
Dec-10-19 07:00AM  Biotech accelerator teams with investment firm for $210M fund raise American City Business Journals +10.93%
Dec-05-19 02:37PM  Edited Transcript of SYBX earnings conference call or presentation 12-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-25-19 04:02PM  Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
04:02PM  Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-14-19 11:41AM  Can Synlogic (NASDAQ:SYBX) Afford To Invest In Growth? Simply Wall St.
Nov-12-19 04:02PM  Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results Business Wire
Nov-07-19 03:07PM  Synlogic, Inc. (SYBX) Is Burning These Hedge Funds Insider Monkey
Nov-05-19 04:02PM  Synlogic Announces Third Quarter 2019 Conference Call and Webcast Business Wire
Sep-30-19 04:02PM  Synlogic to Present at the Chardan 3rd Annual Genetic Medicines Conference Business Wire +8.02%
Sep-26-19 07:00AM  Sherlock Bio gets DoD grant to bring CRISPR to the battlefield American City Business Journals -7.76%
Sep-25-19 05:23PM  Edited Transcript of SYBX earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Sep-12-19 12:56PM  Those Who Purchased Synlogic (NASDAQ:SYBX) Shares A Year Ago Have A 78% Loss To Show For It Simply Wall St.
Sep-06-19 03:46PM  Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure Business Wire -8.53%
Sep-05-19 08:12AM  The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug Benzinga
Sep-04-19 04:01PM  Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure Business Wire -8.49%
06:00AM  Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) Business Wire
Aug-24-19 01:46PM  10 Biopharmaceutical Companies Trying To Cure Cancer Benzinga
Aug-21-19 06:03PM  Synlogic Discontinues Development of SYNB1020, Stock Down Zacks -7.45%
Aug-20-19 07:38AM  Synlogic's stock sinks toward record low after SYNB1020 development discontinued as trial disappoints MarketWatch -27.74%
07:33AM  The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine Benzinga
06:00AM  Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia Business Wire
Aug-08-19 05:00PM  Synlogic to Present at the 2019 Wedbush PacGrow Healthcare Conference Business Wire +5.26%
04:02PM  Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates Business Wire
06:38AM  Microbiome biotechs grapple with how to protect their IP American City Business Journals
Aug-01-19 04:02PM  Synlogic Announces Second Quarter 2019 Conference Call and Webcast Business Wire -7.84%
Jul-25-19 09:54AM  Synlogic Enters Oversold Territory Zacks
Jul-15-19 06:00AM  Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development Business Wire
Jul-01-19 01:10PM  American Gene Technologies: The Software Revolution for the Next 100 Years Zacks Small Cap Research
Jun-12-19 06:30AM  Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic Medicines Business Wire +25.20%
May-23-19 04:15PM  Synlogic (SYBX) Enters Cancer Collaboration with Roche Zacks
May-22-19 07:00AM  Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors Business Wire
May-16-19 09:14PM  Synlogic, Inc. (SYBX) Q1 2019 Earnings Call Transcript Motley Fool
May-15-19 01:12PM  Edited Transcript of SYBX earnings conference call or presentation 9-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-09-19 04:02PM  Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire
May-02-19 04:05PM  Synlogic Announces First Quarter 2019 Conference Call and Webcast Business Wire -8.12%
Apr-30-19 07:00AM  Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic Medicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) Business Wire +10.85%
Apr-26-19 04:26PM  Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer Investor's Business Daily
11:43AM  Could Synlogic, Inc.'s (NASDAQ:SYBX) Investor Composition Influence The Stock Price? Simply Wall St.
Apr-15-19 04:10PM  Synlogic to Present Data from New Solid Oral Formulation Process at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) Business Wire
Apr-09-19 07:00AM  Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer Business Wire
Apr-02-19 04:05PM  Synlogic to Webcast Presentation at the 18th Annual Needham Healthcare Conference Business Wire
Mar-18-19 11:41AM  Edited Transcript of SYBX earnings conference call or presentation 12-Mar-19 12:00pm GMT Thomson Reuters StreetEvents
Mar-13-19 04:05PM  Synlogic to Webcast Presentation at the Oppenheimer 29th Annual Healthcare Conference Business Wire
Mar-12-19 07:00AM  Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Business Wire -7.86%
Mar-06-19 07:00AM  Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic Medicines to Treat Inflammatory Bowel Disease Business Wire -6.87%
Mar-05-19 04:05PM  Synlogic Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast Business Wire
Feb-28-19 05:00PM  Synlogic to Present at Investor Conferences in March Business Wire
Feb-20-19 04:02PM  Synlogic to Webcast Presentation at the SVB Leerink 8th Annual Global Healthcare Conference Business Wire
Feb-12-19 07:00AM  Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of Directors Business Wire +7.30%
Jan-16-19 02:01PM  Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogics Synthetic Biotic Medicine in Development as a Potential Treatment for Hyperammonemia Business Wire
Jan-03-19 08:00AM  Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2019 Catalysts Business Wire
Dec-12-18 07:00AM  Synlogic Expands Capabilities in Manufacturing with the Appointment of Head of Technical Operations and Establishment of In-house Production of Clinical Trial Material for its Synthetic BioticTM Medicines Business Wire
Nov-23-18 08:50AM  Research Report Identifies Synlogic, Consolidated Water Co., AeroCentury, Tecogen, Truett-Hurst, and Marchex with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-20-18 04:05PM  Synlogic to Webcast Presentation at the 30th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-13-18 04:05PM  Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates Business Wire
Nov-12-18 04:23PM  Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) Business Wire
Nov-07-18 04:20PM  Synlogic Announces Third Quarter 2018 Conference Call and Webcast Business Wire
Nov-06-18 08:01AM  Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancers (SITC) 33rd Annual Meeting Business Wire
Nov-05-18 10:30AM  Will Synlogic, Inc (SYBX) Report Negative Earnings Next Week? What You Should Know Zacks
Nov-01-18 04:05PM  Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting Business Wire +5.18%
Oct-02-18 07:00AM  Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer Business Wire
Sep-25-18 04:05PM  Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology Business Wire
07:30AM  Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors Business Wire
Sep-05-18 03:20PM  How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease Investor's Business Daily +18.92%
Sep-04-18 02:30AM  Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU) Business Wire
Aug-29-18 04:05PM  Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference Business Wire
Aug-16-18 06:29AM  Synlogic data shows reduction in disability-causing disease in mice American City Business Journals
Aug-13-18 11:16AM  Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic Medicine as a Potential Treatment for Phenylketonuria Business Wire
Aug-08-18 04:02PM  Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates Business Wire -5.98%
Aug-07-18 04:02PM  Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference Business Wire
Jun-25-18 07:10AM  Synlogic Presents New Preclinical Data from Synthetic Biotic Immuno-Oncology Program at FOCIS 2018 Business Wire -8.45%
07:00AM  Synlogic Joins Russell 3000® Index Business Wire
Jun-11-18 04:02PM  Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria Business Wire
Jun-05-18 09:00AM  Why Synlogic (SYBX) Could Be a Potential Winner Zacks
Jun-04-18 07:00AM  Synlogic Presents New Preclinical Data from Synthetic Biotic Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week® Business Wire
May-24-18 07:38AM  Synlogic (SYBX) Enters Oversold Territory Zacks -5.03%
May-15-18 07:00AM  Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update Business Wire
May-10-18 04:10PM  Synlogic Announces Leadership Change Business Wire
Apr-25-18 07:00AM  Synlogic Receives Fast-Track Designation for SYNB1618, a Synthetic Biotic medicine for the Treatment of Phenylketonuria Business Wire
Apr-18-18 07:00AM  Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of Phenylketonuria Business Wire
Apr-16-18 04:02PM  Synlogic Presents Preclinical Data from Synthetic Biotic Immuno-Oncology Program at the American Association for Cancer Research 2018 Annual Meeting Business Wire
Apr-06-18 08:30AM  Synlogic Announces Registered Direct Offering of Common Stock Business Wire +5.66%
Apr-04-18 07:10AM  Wired News Synlogic Announced First Subject Dosed in Phase-1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis ACCESSWIRE
Apr-02-18 07:00AM  Synlogic Doses First Patient in Phase 1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis Business Wire
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.a.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. The company also has a clinical collaboration with Hoffman-La Roche Ltd. to evaluate SYNB1891 in combination with PD-L1 checkpoint inhibitor in patients with advanced solid tumors. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shea Richard PDirectorDec 13Buy2.747,50020,5507,500Dec 16 05:25 PM
open in yahoo | open in reuters | open in google